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Ultrasonically Responsive Tissue Engineering Scaffolds for the Temporal Control over Osteo-Inductive 
Growth Factor Delivery 
 
Catherine Linh1 and Stephen Kennedy2,3 
1Department of Chemistry, 2Department of Chemical Engineering, 3Department of Electrical, Computer 
and Biomedical Engineering 
University of Rhode Island, Kingston, RI 02881 
 
Introduction 
In 2012, approximately 6.8 million people were diagnosed with orthopedic injuries and diseases1. Over 
500,000 people had undergone bone grafting procedures, which cost 2.5 billion dollars per year5. The 
most common treatment for bone defects is autogenous bone grafting, which usually involves the removal 
of the host’s bone from the pelvis in order to fill the bone defect5. However, these traditional bone 
grafting treatments have complications, such as donor site morbidity, and can result in non-unions at the 
injury site5.  
 
Figure 1. Traditional bone grafting has complications. Biological stimuli have an influence on bone 
regeneration. Delayed healing caused by inappropriate stimuli would result in a bone defect. Figure 
adapted from Mehta et al [5]. 
 
Because of these complications, synthetic bone grafting materials are of great interest. Polymer-based 
grafting scaffolds can provide the 3D structure required to facilitate 3D bone tissue growth. Moreover, 
these scaffolds can be loaded with bioactive molecules that direct bone tissue development, delivering 
them in a localized, sustained manner through polymer degradation and/or diffusion.  
 
Bone regeneration requires biomaterial scaffold implantation and can be potentially enhanced by 
incorporating growth factors. Kolambkar conducted a study on bone regeneration of an 8 mm critical 
defect, which was filled with the biomaterial scaffold (alginate and nanofiber mesh) and bone 
morphogenic protein or BMP-2 (3). The bone regeneration that resulted from the (i) biomaterial scaffold 
and (ii) biomaterial scaffold with BMP-2 was analyzed by micro computed tomography (μCT) at 4 and 12 
weeks3. There is significant bone regeneration from the biomaterial and BMP-2, compared to the 
biomaterial scaffold alone. There was another study done by Lee on the bone regeneration of rat cranial 
defects by calcium phosphate cement (CPC)4. These defects had been filled with scaffolds incorporated 
with either no growth factor (i), BMP-2 (ii), or BMP-2 & transforming growth factor beta-1, or TGFβ-1 
(iii) were analyzed by μCT4. The CPC scaffold alone has some effect on bone regeneration. Accompanied 
with BMP-2, the defect is nearly filled in with bone tissue. Lee and his colleagues attempted to see if they 
could improve the bone regeneration by having BMP-2 and TGFβ-1 at the same time inside the scaffold. 
The bone regeneration actually worsened, compared to having BMP-2 alone. This happened because the 
cells were directed to proliferate and to osteo-differentiate at the same time. Once the stem cells become 
osteoblasts, these cells lose the ability to divide rapidly.  
 
Figure 2. Bone regeneration requires biomaterial scaffold implantation and can be potentially 
enhanced by incorporating growth factors. (A) An 8 mm critical defect was filled with the biomaterial 
scaffold. (B) The bone regeneration that resulted from the biomaterial scaffold (i) and biomaterial 
scaffold with BMP-2 (ii) was analyzed by micro computed tomography (μCT). Figures adapted from 
Kolambkar et al [3]. (C) The rat cranial defects that have been filled with scaffolds incorporated with no 
growth factor (i), BMP-2 (ii), or BMP-2 & TGFb-1 (iii) were analyzed by μCT. Figure adapted from Lee 
et al [4]. 
 
However, bone regeneration requires the orchestration of a sequence of events (i.e., bone progenitor cell 
recruitment, proliferation, and osteo-differentiation). The bone progenitor cells are first recruited into the 
cell. Then, these cells proliferate and multiply into many cells. At a later point in time, these cells undergo 




Figure 3. The natural bone healing cascade suggests that SDF-1⍺ (recruiting factor) be delivered 
prior to delivery of BMP-2 (differentiation factor). (A) Schematic of the path of MSC from stem cell 
to osteocyte. (B) Schematic of native bone repair sequence. Figures adapted from Mehta et al [5]. 
 
Project Aims 
The problem is that bone regeneration needs a scaffold to deliver signals in sequence to cells. We 
hypothesized that an ultrasonically responsive hydrogel-based biomaterial system that can potentially 
deliver growth factors in sequence. Specifically, we aimed to design a polymer scaffold that can release 
one payload diffusively at early time points, followed by ultrasonically triggered release of a second 
payload. The ability to deliver sequential payloads on demand (using ultrasonic stimulation) can more 
accurately mimic natural biological responses and afford the ability to clinically alter the course of 
therapies after scaffold implantation. Calcium-crosslinked alginate hydrogels have self-healing properties, 
allowing them to potentially recover from damage caused by ultrasonic exposures2. The crosslinking 
between the calcium and alginate is disrupted in the presence of ultrasound stimulation and reforms in the 
absence of ultrasound.  
 
Figure 4. Ultrasonically responsive biomaterials have potential in sequential delivery. Schematic of 
the disruption of the crosslinking in the presence of ultrasound and its self-healing properties in the 






Figure 5. We used four model drugs of different sizes and charges.  
 
The calcium alginate hydrogels were loaded with four model drugs (fluorescently labeled dextrans) of 
different charges and sizes in order to characterize drug release due to diffusion (controls, no ultrasonic 
signal applied), compared to when stimulated by different ultrasonic signals (different amplitudes and 
durations of 20 kHz signals). The figure below depicts the process of making and testing calcium-
crosslinked alginate hydrogels. Release of these dextrans was quantitatively measured on a plate reader 
against a standard curve by measuring fluorescence at 525 nm. 
 
Figure 6. Process of making and testing calcium-crosslinked alginate hydrogels. (i) 2.5% wt alginate 
was cast with a model drug and calcium sulfate on a glass plate. (ii) Individual gels were cut. (iii) Gels 
were rinsed in 5 mL of PBS containing CaCl2 and MgCl2. (iv) Gels before ultrasound stimulation. (v) 
Gels were ultrasonically stimulated at different amplitudes and durations. (vi) 1 mL samples were 









Results and Discussion 
 
Figure 7. The optimal ultrasound stimulation for triggering release was a 20 kHz signal at 20% 
amplitude for 3 minutes due to a combination of release, thermal, and structural considerations. 
(A) Percent release (i) and rise in temperature (ii) after ultrasonic stimulation at various amplitudes (0, 20 
and 40%) and durations (1 and 3 min; blue and orange, respectively). (B) Temperature achieved at the 
indicated ultrasonic stimulations (i) and percent of released due to diffusion at the maximum temperature 
achieved during stimulation (ii). (C) Photograms of the ultrasonically responsive hydrogels after the 
indicated ultrasonic stimulations: 1 minute (top row) and 3 minute (bottom row) exposures. In parts A, B, 
and C, ‡ indicates the optimized ultrasonic stimulation condition.  n.s., *, **, and *** indicate statistical 
comparisons that were not statistically significant (n.s.), or significant with p < 0.05, 0.01, or 0.001, 
respectively.  N = 4.  
 
 
The optimal ultrasound stimulation for triggering release was a 20 kHz signal at 20% amplitude for 3 
minutes due to a combination of release, thermal, and structural considerations. In figure 7 part A, percent 
release (i) and rise in temperature (ii) were measured after ultrasonic stimulation at various amplitudes (0, 
20 and 40%) and durations (1 and 3 min; blue and orange, respectively). There is a significant release of 
the model drug from 20% and 40% amplitude at 3 minutes, compared to the controls. Ultrasound 
stimulation also increases the temperature of the solution. Because of the 14 °C temperature increase, 
40% amplitude for 3 minutes was not chosen as the optimal stimulation. Temperature is crucial because 
proteins denature and lose their bioactivity at 45 °C. Since 20% amplitude for 3 minutes resulted in a 5 °C 
temperature increase, proteins would still have their bioactivity. In part B, the temperature achieved after 
each ultrasonic stimulation (i) and percent of released due to diffusion at the maximum temperature 
achieved during stimulation (ii) were measured. There was no significant difference in drug release at 
room temperature and elevated temperature, indicating that the release is solely due to the ultrasonic 
stimulation and not heat. In part C, photographs of the ultrasonically responsive hydrogels were taken 
after each ultrasonic stimulations, where the top row shows 1 minute exposure and the bottom row shows 
3 minute exposure. After being exposed to ultrasound at 20% amplitude for 3 minutes, the morphology of 
the gel was intact, where the 3D structure of the scaffold was preserved. In comparison to the gel after 






Figure 8. Charged model drugs could be retained in the hydrogels prior to ultrasound stimulation. 
(A) Percent release due to 3 minutes of ultrasonic stimulation at 0% amplitude as a function of molecular 
charge for small (purple) and large (aqua) dextrans. (B) Percent release due to diffusion (0%) and after 
being exposed to 20% ultrasonic amplitude for 3 minutes for small (purple) and large (aqua) cationic 
dextrans. (C) Cumulative release vs. time for 10 kDa uncharged dextran (blue) and 3-6 kDa cationic 
dextran (red). Red rectangle indicates when gels were exposed to ultrasound. (D) Cumulative release vs. 
time of SDF-1a (blue) and BMP-2 (green). Gray rectangle indicates when gels were exposed to 
ultrasound. For all parts, n.s., *, **, and *** indicate statistical comparisons that were not statistically 
significant (n.s.), or significant with p < 0.05, 0.01, or 0.001, respectively.  N = 4.  
 
Charged model drugs could be retained in the hydrogels prior to ultrasound stimulation. In part A, the 
percent releases due to 3 minutes of ultrasonic stimulation at 0% amplitude are represented as a function 
of molecular charge for small (purple) and large (aqua) dextrans. The neutral drugs tended to diffuse out 
of the scaffold prior to stimulation, while the charged drugs were retained in the scaffold prior to 
stimulation. In part B, the percent release due to diffusion (0%) and after being exposed to 20% ultrasonic 
amplitude for 3 minutes was measured for small (purple) and large (aqua) cationic dextrans. The small 
charged drug was retained and then was ultrasonically released in an on-demand manner. The large 
charged drug was still retained after ultrasound stimulation. In part C, the cumulative release vs. time for 
10 kDa uncharged dextran (blue) and 3-6 kDa cationic dextran (red) was measured. Red rectangle 
indicates when gels were exposed to ultrasound for 3 minutes at 20% amplitude for every hour. The 
uncharged dextran was released at a faster rate than the charged dextran through diffusion. The charged 
dextran was retained in the scaffold until it is released by ultrasonic stimulation, resulting in a cumulative 
release of approximately 3 μg. The uncharged dextran was also released by ultrasonic stimulation where 
the cumulative release was approximately 12 μg. For both uncharged and charged dextrans, there was a 
significant difference in the release by diffusion and ultrasound stimulation. In part D, the cumulative 
release vs. time of SDF-1α (blue) and BMP-2 (green) was measured. Gray rectangle indicates when gels 
were exposed to ultrasound for 3 minutes at 20% amplitude for every 15 minutes. SDF-1α was released at 
a faster rate than the charged dextran through diffusion. The BMP-2 was retained in the scaffold until it is 
released by ultrasonic stimulation, resulting in a cumulative release of approximately 58 ng. The SDF-1α 
was also released by ultrasonic stimulation where the cumulative release was approximately 75 ng. For 
both SDF-1α and BMP-2, there was a significant difference in the release by diffusion and ultrasound 
stimulation.  
The publication of this study is pending.  
 
Conclusion 
An ultrasonically responsive calcium-crosslinked hydrogel system could provide delayed release of small, 
charged model drugs and differentiating BMP-2. This system can be used to investigate how the timing 
and sequence of drugs based on their size and charge and can be applied to bone regeneration in the 
delivery of growth factors. 
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